These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30206670)

  • 1. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
    Saiki O; Uda H
    Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals.
    Saiki O; Uda H
    Clin Exp Rheumatol; 2017; 35(4):666-670. PubMed ID: 28229812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
    Ahmadzadeh A; Farahmand AN; Gachkar L
    Int J Rheum Dis; 2017 Feb; 20(2):231-237. PubMed ID: 26385018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
    Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T;
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
    Ogata A; Atsumi T; Fukuda T; Hirabayashi Y; Inaba M; Ishiguro N; Kai M; Kawabata D; Kida D; Kohsaka H; Matsumura R; Minota S; Mukai M; Sumida T; Takasugi K; Tamaki S; Takeuchi T; Ueda A; Yamamoto K; Yamanaka H; Yoshifuji H; Nomura A;
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1354-62. PubMed ID: 25832859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
    Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
    Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
    Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
    Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis.
    Kikuchi J; Kondo T; Shibata A; Sakai R; Okada Y; Chino K; Okuyama A; Kurasawa T; Takei H; Amano K
    Mod Rheumatol; 2018 May; 28(3):444-451. PubMed ID: 28849709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
    Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP
    Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
    Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis.
    Saito S; Kaneko Y; Izumi K; Takeuchi T
    J Rheumatol; 2017 May; 44(5):553-557. PubMed ID: 28298563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
    Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.